Author at Microdose

James Hallifax

James Hallifax is a writer and journalist who covers the psychedelic medicines space. After originally founding The Psychedelic Investor, James worked with Psychedelic Spotlight for a year, before going freelance. He now writes weekly for Microdose.buzz, and other publications.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Culture

16 Nov 2022

Elon Talks Psychedelics: Is he Helping or Hurting the Movement?

The famous billionaire has tweeted about psychedelics again....

By James Hallifax

Law & Politics

10 Nov 2022

Colorado Votes to Legalize Psilocybin Therapy; Allow Personal Use of Psychedelics

Colorado’s Proposition 122, a ballot initiative to permit the personal consumption of many “natural” psychedelics, and legalize psilocybin-assisted psychotherapy in regulated “healing centers....

By James Hallifax

Law & Politics

2 Nov 2022

Will Colorado Voters Legalize Psychedelics?

Colorado will finally vote on Proposition 122, which — if passed — would make the state the most psychedelic-friendly in the union....

By James Hallifax

Industry

25 Oct 2022

A Deeper Look at Atai Life Sciences’ R&D Day

Today, atai Life Sciences (Nasdaq: ATAI) held its much anticipated R&D Day, where management and scientific leaders walked investors through the company’s diverse medical pipeline....

By James Hallifax

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News, Industry

12 Oct 2022

Breaking News: Compass Pathways to run TWO Phase 3 Trials for Depression

Today, psychedelic medicine company Compass Pathways (Nasdaq: CMPS) announced a major update: rather than conducting just one Phase 3 clinical trial attempting to treat Treatment-Resistant Depression (TRD) with psilocybin-assisted therapy,...

By James Hallifax

Industry

7 Oct 2022

atai Life Sciences Doses First Patient in New DMT Clinical Trial

On Wednesday, atai published a press release celebrating the first patient being dosed in their Phase 1 DMT safety trial....

By James Hallifax

Finance

6 Oct 2022

Can Psychedelic Stocks Like MindMed and atai Ever Recover?

Should investors begin ringing the funeral bells for psychedelic stocks? Can psychedelic stocks Like MindMed and atai ever recover? James Hallifax takes a deeper look....

By James Hallifax

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

James Hallifax is a writer and journalist who covers the psychedelic medicines space. After originally founding The Psychedelic Investor, James worked with Psychedelic Spotlight for a year, before going freelance. He now writes weekly for Microdose.buzz, and other publications.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads